DK3030557T3 - Hidtil ukendte phtalazinonderivater og fremgangsmåde til fremstilling deraf - Google Patents

Hidtil ukendte phtalazinonderivater og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK3030557T3
DK3030557T3 DK14843941.7T DK14843941T DK3030557T3 DK 3030557 T3 DK3030557 T3 DK 3030557T3 DK 14843941 T DK14843941 T DK 14843941T DK 3030557 T3 DK3030557 T3 DK 3030557T3
Authority
DK
Denmark
Prior art keywords
manufacture
previously unknown
phthalazine derivatives
phthalazine
derivatives
Prior art date
Application number
DK14843941.7T
Other languages
Danish (da)
English (en)
Inventor
Jae-Hoon Kang
Hong-Sub Lee
Yoon-Suk Lee
Joon-Tae Park
Kyung-Mi An
Jin-Ah Jeong
Kyung-Sun Kim
Jeong-Geun Kim
Chang-Hee Hong
Sun-Young Park
Dong-Keun Song
Yong-Don Yun
Original Assignee
Idience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co Ltd filed Critical Idience Co Ltd
Application granted granted Critical
Publication of DK3030557T3 publication Critical patent/DK3030557T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK14843941.7T 2013-09-13 2014-09-12 Hidtil ukendte phtalazinonderivater og fremgangsmåde til fremstilling deraf DK3030557T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130110170 2013-09-13
KR1020140120152A KR101670126B1 (ko) 2013-09-13 2014-09-11 신규 프탈라지논 유도체 및 그 제조방법
PCT/KR2014/008523 WO2015037939A1 (en) 2013-09-13 2014-09-12 A novel phtalazinone derivatives and manufacturing process thereof

Publications (1)

Publication Number Publication Date
DK3030557T3 true DK3030557T3 (da) 2023-09-04

Family

ID=53024930

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14843941.7T DK3030557T3 (da) 2013-09-13 2014-09-12 Hidtil ukendte phtalazinonderivater og fremgangsmåde til fremstilling deraf

Country Status (25)

Country Link
US (3) US9682973B2 (OSRAM)
EP (1) EP3030557B1 (OSRAM)
JP (1) JP6180643B2 (OSRAM)
KR (1) KR101670126B1 (OSRAM)
CN (1) CN105793248B (OSRAM)
AU (1) AU2014319132C1 (OSRAM)
BR (1) BR112016004979B1 (OSRAM)
CA (1) CA2923614C (OSRAM)
DK (1) DK3030557T3 (OSRAM)
ES (1) ES2953834T3 (OSRAM)
FI (1) FI3030557T3 (OSRAM)
HR (1) HRP20230998T1 (OSRAM)
HU (1) HUE062770T2 (OSRAM)
IL (1) IL244548B (OSRAM)
LT (1) LT3030557T (OSRAM)
MX (1) MX379467B (OSRAM)
MY (1) MY195343A (OSRAM)
PL (1) PL3030557T3 (OSRAM)
PT (1) PT3030557T (OSRAM)
RS (1) RS64477B1 (OSRAM)
RU (1) RU2636585C2 (OSRAM)
SG (1) SG11201600549TA (OSRAM)
SI (1) SI3030557T1 (OSRAM)
SM (1) SMT202300268T1 (OSRAM)
WO (1) WO2015037939A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
US11542282B2 (en) 2018-02-28 2023-01-03 The Trustees Of The University Of Pennsylvania Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents
BR112022021321A2 (pt) * 2020-04-21 2022-12-20 Idience Co Ltd Formas cristalinas do composto de ftalazinona.
US12060345B2 (en) 2020-04-21 2024-08-13 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
EP4148046A4 (en) * 2020-05-08 2024-07-24 Txinno Bioscience Inc. NEW PHTHALAZINE DERIVATIVE WITH ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE INHIBITING ACTIVITY AND USE THEREOF
US12059419B2 (en) * 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US20230391752A1 (en) * 2020-10-22 2023-12-07 Chulalongkorn University Pyrrolidine-3-carboxamide derivatives and related uses
KR20220125183A (ko) 2021-03-04 2022-09-14 아이디언스 주식회사 Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도
WO2022186649A1 (ko) * 2021-03-04 2022-09-09 아이디언스 주식회사 Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도
TW202313040A (zh) * 2021-06-02 2023-04-01 南韓商愛迪恩斯股份有限公司 以酞嗪酮衍生物治療病症的方法
WO2023144626A1 (en) * 2022-01-25 2023-08-03 Idience Co., Ltd. Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
WO2024025389A1 (ko) * 2022-07-29 2024-02-01 아이디언스 주식회사 프탈라지논 유도체의 중간체의 제조방법
CN117229260B (zh) * 2023-11-13 2024-02-27 中国药科大学 DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2384776C (en) 2000-10-30 2006-02-03 Kudos Pharm Ltd Phthalazinone derivatives
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
KR101146806B1 (ko) 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
AU2007266840B2 (en) 2006-05-31 2012-09-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
SI2698062T1 (sl) 2006-12-28 2015-12-31 Abbvie Inc. Inhibitorji poli (ADP-riboza) polimeraze
CN101030723A (zh) 2007-04-04 2007-09-05 钟志华 电磁变相发动机
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
UY31603A1 (es) * 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2598491B1 (en) 2010-07-27 2015-09-02 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
ES2590682T3 (es) * 2010-12-02 2016-11-23 Shanghai De Novo Pharmatech Co Ltd. Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법

Also Published As

Publication number Publication date
HUE062770T2 (hu) 2023-12-28
US9682973B2 (en) 2017-06-20
IL244548B (en) 2020-10-29
RU2016108038A (ru) 2017-09-07
AU2014319132B2 (en) 2016-07-07
EP3030557B1 (en) 2023-05-31
ES2953834T3 (es) 2023-11-16
RU2636585C2 (ru) 2017-11-24
HK1224280A1 (zh) 2017-08-18
CN105793248A (zh) 2016-07-20
CA2923614A1 (en) 2015-03-19
AU2014319132C1 (en) 2020-09-03
IL244548A0 (en) 2016-04-21
USRE49338E1 (en) 2022-12-20
BR112016004979A2 (pt) 2020-05-12
MX2016002998A (es) 2016-06-02
JP6180643B2 (ja) 2017-08-16
EP3030557A1 (en) 2016-06-15
CN105793248B (zh) 2019-08-16
FI3030557T3 (fi) 2023-08-21
HRP20230998T1 (hr) 2023-12-08
SMT202300268T1 (it) 2023-09-06
MY195343A (en) 2023-01-13
WO2015037939A1 (en) 2015-03-19
KR20150031196A (ko) 2015-03-23
CA2923614C (en) 2017-06-27
PL3030557T3 (pl) 2023-10-16
US20170182045A1 (en) 2017-06-29
EP3030557A4 (en) 2017-03-22
KR101670126B1 (ko) 2016-10-27
JP2016534143A (ja) 2016-11-04
MX379467B (es) 2025-03-10
US20160222003A1 (en) 2016-08-04
US9844550B2 (en) 2017-12-19
SG11201600549TA (en) 2016-02-26
BR112016004979B1 (pt) 2023-01-10
PT3030557T (pt) 2023-09-04
LT3030557T (lt) 2023-09-11
AU2014319132A1 (en) 2016-02-11
SI3030557T1 (sl) 2023-11-30
RS64477B1 (sr) 2023-09-29

Similar Documents

Publication Publication Date Title
DK3030557T3 (da) Hidtil ukendte phtalazinonderivater og fremgangsmåde til fremstilling deraf
DK3406633T3 (da) Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
DK2970896T3 (da) Manipulerede levervæv, arrays deraf og fremgangsmåder til fremstilling heraf
DK3019200T3 (da) Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3572527T3 (da) Fremgangsmåder og præparater til fremstilling af nukleinsyrebiblioteker
DK3030092T3 (da) System og fremgangsmåde til fremstilling af et ekstruderet proteinprodukt
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3010841T3 (da) Systemer og fremgangsmåder til ordrebehandling
DK3003699T3 (da) Fodtøjsgenstand og fremgangsmåden til dannelse af genstanden
DK3016741T3 (da) Fremgangsmåde til fremstilling af zeolitter og zeotyper
DK2999103T3 (da) Konverter og fremgangsmåde til styring deraf
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3083680T3 (da) Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3008852T6 (da) System og fremgangsmåde til kryptering
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2955757T3 (da) Nitrid-effektkomponent og fremgangsmåde til fremstilling deraf
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf
DK3365164T3 (da) Forbedringer inden for tabletproduktion
DK3151943T3 (da) Filterpanel og fremgangsmåde til fremstilling heraf
DK3060922T3 (da) Fremgangsmåde og anordning til proteinfremstilling
DK3014315T3 (da) Fremgangsmåde og system til brudbarhedsmåling
DK3066089T3 (da) Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser